Corticosteroid Use for Paradoxical Reactions during Antibiotic Treatment for Mycobacterium ulcerans

PLoS Neglected Tropical Diseases

Volumn 6, Issue 9, 2012, Pages

  Friedman, N Deborah ^a   McDonald, Anthony H ^a   Robson, Michael E ^b   O'Brien, Daniel P ^a,c  

^a Barwon Health ^*  (Australia)

^b St John of God Pathology   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BURULI ULCER; CELL INFILTRATION; CHILD; DEBRIDEMENT; DRUG DOSE REDUCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ULCERANS; NECROSIS; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN BIOPSY; SKIN DEFECT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOPSY; BURULI ULCER; CHILD; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MIDDLE AGED; MYCOBACTERIUM ULCERANS; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866934291     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001767     Document Type: Article

References (18)

1. O'Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, et al. (2007) Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a South-eastern Australian case series. Med J Aust 186: 58-61.
2. O'Brien DP, McDonald A, Callan P, Robson M, Friedman ND, et al. (2012) Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 6: e1473 doi:10.1371/journal.pntd.0001473.
3. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664-672.
4. Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, et al. (2011) Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 52: 94-96.
5. World Health Organization (2004) Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease. Geneva: WHO.
6. Beishuizen SJE, Geerlings SE, (2009) Immune reconstitution inflammatory syndrome: immunopathogenesis, risk factors, diagnosis, treatment and prevention. Netherlands Journal of Medicine 67: 327-331.
7. Walker SL, Lockwood DN, (2008) Leprosy type 1 (reversal) reactions and their management. Lepr Rev 79: 372-386.
8. Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS. Clin Infect Dis 46: e56-e60.
9. Carvalho AC, De Laco G, Saleri N, Pini A, Capone S, et al. (2006) Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis 42: 893-895.
10. O'Brien DP, (2009) "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aus 191: 564-566.
11. Nienhuis WA, Stienstra Y, Mohammed Abass K, Tuah W, Thompson WA, et al. (2012) Paradoxical responses after start of antimicrobial treatment in mycobacterium ulcerans infection. Clin Infect Dis 54: 519-526.
12. Meintjes GA, (2010) Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24: 2381-2390.
13. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, et al. (2003) Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 9: 651-656.
14. Schutte D, Umboock A, Pluschke G, (2009) Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol 160: 273-283.
15. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, Salavert M, Vidal R, et al. (2005) Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40: 756-759.
16. Finch CK, Chrisman CR, Baciewicz AM, Self TH, (2002) Rifampin and rifabutin drug interactions: an update. Arch Intern Med 162: 985-992.
17. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ, (1983) Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 286: 923.
18. Khasawneh F, Sreedhar R, Chundi V, (2009) Strongyloides hyperinfection: an unusual cause of respiratory failure. Ann Intern Med 150: 570-571.